DocGo Inc.

DocGo Inc. (DCGO) Market Cap

DocGo Inc. has a market capitalization of $64.3M.

Price: $0.65

-0.02 (-2.44%)

Market Cap: 64.27M

NASDAQ · time unavailable

CEO: Lee Bienstock

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 2020-12-17

Website: https://www.docgo.com

DocGo Inc. (DCGO) - Company Information

Market Cap: 64.27M|Sector: Healthcare

Company Profile

DocGo Inc. is a company dedicated to providing mobile healthcare solutions and medical transportation for a wide array of healthcare organizations in both the United States and the United Kingdom. Their transportation portfolio includes critical emergency response, alongside routine non-emergency transfers facilitated by ambulance and specialized wheelchair-accessible vehicles. Additionally, DocGo offers a range of mobile health services, delivered directly to patients' homes and offices through its advanced digital platform. These services further extend to include COVID-19 diagnostic testing and comprehensive on-site healthcare support for various events, such as large sporting competitions and concerts. The company was founded in 2015 and is headquartered in New York, New York.

Analyst Sentiment

77%
Strong Buy

From 5 Active Polls

1Y Forecast: $5.84

▲ +797.6% Potential Upside

Consensus Target Metrics

Low Bound

$2

Median

$5

High Bound

$11

Average

$6

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$5.84
▲ +797.63% Upside
Low Target
$1.50
131% Risk
Median Target
$5.42
734% Mid
High Target
$11.00
1591% Max
Consensus
Buy
7 / 8 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)646286136155268432339298
Enterprise Value ($M)57556492112250400306286
Price to Earnings Ratio (P/E)-0.34-1.05-0.16-1.21-3.57-7.13-33.1315.4011.43
Price/Earnings-to-Growth Ratio (PEG)-1.28-0.03
Price to Sales Ratio (P/S)0.210.821.151.921.932.793.582.441.81
Price to Book Ratio (P/B)0.490.470.600.500.520.871.351.040.95
Price to Free Cash Flow Ratio (P/FCF)4.66-10.80-6.831346.744.8535.8835.3611.458.51
Enterprise Value to Sales (EV/Sales)0.730.861.301.392.603.312.211.73
Enterprise Value to EBITDA (EV/EBITDA)-0.37-3.94-0.60-4.34-8.27-23.56-126.5722.3419.99
Debt to Equity Ratio0.050.220.200.110.200.200.180.180.17

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 DOCGO INC (DCGO) — Investment Overview

🧩 Business Model Overview

DOCGO provides transportation and mobility-management services tied to healthcare access, primarily through contracts with health plans, government programs, and related healthcare stakeholders. The operational backbone is a logistics and scheduling layer that matches eligible patients to appropriate transportation options while meeting service-level requirements (timeliness, documentation, accessibility needs, and compliance). This places DOCGO between healthcare payers/providers on the demand side and a network of drivers/transport providers and scheduling workflows on the supply side.

The value proposition is not “rides” in isolation; it is managed transportation operations with auditability—turning complex eligibility rules, route constraints, and documentation requirements into operational processes that reduce payer friction and support continuity of care (e.g., patient access to appointments and post-acute workflows).

💰 Revenue Streams & Monetisation Model

Revenue is primarily contract-driven and largely derived from managed transportation services rather than one-off consumer mobility. Monetisation typically follows a mix of:

  • Managed transportation fees tied to service delivery for defined patient populations or geographies.
  • Transaction-based transportation revenue where billing scales with trip volume, utilization, and required assistance levels.
  • Technology-enabled operations where the software layer reduces operational cost-to-serve and improves claim/documentation quality (often embedded within service contracts rather than priced separately).

Margin structure is influenced by the ability to control cost-to-serve (driver sourcing, dispatch efficiency, route utilization, and service failures), maintain documentation/claims quality (to minimize denials and compliance costs), and preserve contract economics in the face of reimbursement and service-level changes.

🧠 Competitive Advantages & Market Positioning

DOCGO’s moat is best characterized as a blend of regulatory/contract switching costs and operational execution advantages, supported by data and process know-how.

  • High switching costs (contract + compliance): Healthcare transportation programs involve licensing, reporting, eligibility workflows, quality metrics, and compliance requirements. Replacing an incumbent provider creates administrative burden and service-risk for payers, making contract transitions difficult.
  • Process and data advantage: Over time, operational learning improves dispatch accuracy, reduces missed trips/service failures, and strengthens documentation/claims handling—factors that directly affect reimbursement realization.
  • Scale economics in logistics: Managed networks benefit from better matching of supply (drivers/providers) to demand (eligible trips), improving utilization and lowering unit costs.

Competitive benchmarking:

  • MTM (Medical Transportation Management) — a large, established NEMT manager with broad payer/state relationships, emphasizing mature operational controls at scale.
  • Modivcare (LogistiCare legacy) — a major NEMT broker/manager with extensive program coverage.
  • TripSpark — another prominent NEMT and mobility management provider with a strong technology and operations focus.

Compared with these rivals, DOCGO’s industry focus centers on healthcare-linked transportation operations delivered through a technology-enabled execution model. The differentiator is the ability to run contract-grade logistics (eligibility, scheduling, documentation, and service-level adherence) while controlling cost-to-serve—attributes that matter to payers that manage utilization and compliance risk.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, DOCGO’s addressable market expands through structural demand for healthcare access and the maturation of managed transportation procurement.

  • Aging demographics and higher healthcare utilization: More patients require mobility support for outpatient care, diagnostics, and post-acute follow-up.
  • Continued reliance on Medicaid and managed care programs: Transportation access remains a recurring obligation tied to eligible populations, supporting repeatable demand.
  • Operational outsourcing trends: Payers increasingly externalize transportation logistics to reduce administrative overhead and improve measurable service outcomes.
  • Digitalization and process automation: Technology-enabled dispatch, eligibility workflows, and documentation improve throughput and reduce administrative friction, supporting higher service reliability and better unit economics.
  • Geographic and contract expansion: Incremental state/payer wins expand the network density that can lower unit costs and strengthen execution.

⚠ Risk Factors to Monitor

  • Contract and reimbursement pressure: Managed service economics can be exposed to reimbursement adjustments, contract re-bids, and changes in utilization patterns.
  • Service-level and compliance risk: Healthcare-linked transportation requires strict adherence to documentation, eligibility verification, and timeliness standards; failures can lead to clawbacks, penalties, or contract loss.
  • Fraud, waste, and documentation integrity: Transportation programs can face higher scrutiny; weak controls can increase claim denials, audits, and regulatory exposure.
  • Labor and capacity constraints: Driver/provider availability and utilization variability can impact on-time performance and unit costs.
  • Technology execution and data privacy: Systems must reliably handle scheduling complexity and sensitive health-linked information under privacy and security requirements.

📊 Valuation & Market View

The market often values transportation and managed services businesses on EV/Revenue and EV/EBITDA, with investor focus typically shifting toward:

  • Margin trajectory driven by cost-to-serve improvements and reduced service failures/denials.
  • Contract durability (renewal visibility and evidence of re-bid performance).
  • Unit economics such as effective utilization, documentation quality, and operational productivity.
  • Operating leverage as network density improves dispatch efficiency and supply utilization.

Because much of the business is contract-mediated and compliance-driven, valuation tends to reward operators that demonstrate repeatable execution and a defensible quality-and-cost profile over time.

🔍 Investment Takeaway

DOCGO’s long-term investment case rests on defensibility from contract-driven switching costs and a compounding execution/data advantage in healthcare transportation logistics. The business can benefit from structural demand for patient access to care and the outsourcing trend in managed transportation, provided it maintains compliance-grade service delivery and cost-to-serve discipline amid reimbursement and operational capacity pressures.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for DCGO.

prnewswire.com2026-07-03

Did DocGo Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

seekingalpha.com2026-06-08

DocGo Inc. (DCGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

DocGo Inc. (DCGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

gurufocus.com2026-06-03

DocGo Launches Mobile Phlebotomy Services in South Florida

DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health and medical transportation services, today

businesswire.com2026-06-03

DocGo Launches Mobile Phlebotomy Services in South Florida

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health and medical transportation services, today announced that its PTI Health by DocGo subsidiary has launched mobile phlebotomy services in Southern Florida. In conjunction with this launch, PTI Health has expanded its relationship with a major national clinical laboratory to cover services throughout the Southeast and will work collaboratively with this lab partne.

marketbeat.com2026-05-16

DocGo Targets Profitability as It Pivots to Mobile Health, Medical Transport

DocGo NASDAQ: DCGO Chief Executive Officer Lee Bienstock outlined the company's transition away from COVID-related, migrant and emergency-response programs and toward its “evergreen” medical transportation and mobile health businesses during a presentation at the 21st Annual Needham Technology, Media, and Consumer Conference.

seekingalpha.com2026-05-12

DocGo Inc. (DCGO) Q1 2026 Earnings Call Transcript

DocGo Inc. (DCGO) Q1 2026 Earnings Call Transcript

marketbeat.com2026-05-11

DocGo Q1 Earnings Call Highlights

DocGo NASDAQ: DCGO reported first-quarter revenue of $75.6 million and an adjusted EBITDA loss of $10.2 million, as executives pointed to accelerating demand in virtual care, medical transportation and mobile health services while acknowledging pressure from fuel costs and labor-related investments.

zacks.com2026-05-11

DocGo Inc. (DCGO) Reports Q1 Loss, Beats Revenue Estimates

DocGo Inc. (DCGO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.09 per share a year ago.

businesswire.com2026-05-11

DocGo Announces First Quarter 2026 Results

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health and medical transportation services, today announced financial and operating results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Total revenue for the first quarter of 2026 was $75.6 million, compared to $96.0 million in the first quarter of 2025. This decline was entirely due to the wind-down of migrant-related programs,.

businesswire.com2026-05-06

DocGo Announces Upcoming Participation at the 21st Annual Needham Technology, Media, & Consumer Conference

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo”), a leading provider of technology-enabled medical transportation and mobile health services, announced today that Lee Bienstock, Chief Executive Officer, will deliver a company presentation at the 21st Annual Needham Technology, Media, & Consumer Conference on Thursday, May 14, at 11:45 – 12:25 PM Eastern Time, and will be participating in 1x1 meetings at this event. A webcast of the presentation will be available on the investo.

businesswire.com2026-04-27

DocGo to Announce First Quarter 2026 Results on Monday, May 11, 2026

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled medical transportation and mobile health services, announced today that the Company will release its financial results for the first quarter ended March 31, 2026 after the markets close on Monday, May 11, 2026. Management will also host a conference call to discuss these results at 5:00 p.m. ET on that day. Conference call and webcast details: Monday, May 11, 2026 5:00 p.m.

defenseworld.net2026-04-07

Analysts Set DocGo Inc. (NASDAQ:DCGO) PT at $2.38

Shares of DocGo Inc. (NASDAQ: DCGO - Get Free Report) have earned an average rating of "Hold" from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company.

defenseworld.net2026-04-03

Head-To-Head Survey: DocGo (NASDAQ:DCGO) vs. CochLear (OTCMKTS:CHEOY)

DocGo (NASDAQ: DCGO - Get Free Report) and CochLear (OTCMKTS:CHEOY - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk. Analyst Recommendations This is a summary of recent ratings and

businesswire.com2026-03-18

Ethisphere Names DocGo as One of the 2026 World's Most Ethical Companies®

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled medical transportation and mobile health services, announced today that it has been recognized as one of the 2026 World's Most Ethical Companies® by Ethisphere, a global leader in defining and advancing the standards of ethical business practices. This is DocGo's first time receiving this honor, and the Company is one of only four honorees in the healthcare providers and ser.

seekingalpha.com2026-03-17

DocGo Inc. (DCGO) Q4 2025 Earnings Call Transcript

DocGo Inc. (DCGO) Q4 2025 Earnings Call Transcript

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"DCGO reported Q1 2026 revenue of $75.55B with gross margin of 31.6%. EPS was -$0.15 and net income was -$14.76B (net margin -19.5%). On a YoY basis, revenue was down sharply versus Q1 2025 ($96.03B; ~-21.4%), and net income was more negative (Q1 2025 net income -$9.41B to Q1 2026 -$14.76B; ~-57.0%). QoQ, revenue rose slightly from Q4 2025 ($74.94B to $75.55B; ~+0.8%), but losses deepened (Q4 2025 net income -$0.13B to Q1 2026 -$14.76B). Profitability remains weak: operating margin stayed negative and deteriorated meaningfully, falling to -24.8% in Q1 2026 from -43.3% in Q4 2025 but worsening versus the prior-year quarters as scale and cost structure remain challenging. Cash flow quality is inconsistent—operating cash flow was -$4.66B in Q1 2026, compared with -$0.01B in Q4 2025 and +$0.34B in Q2 2025. Balance sheet resilience is mixed: cash and short-term investments were very large ($46.82T) versus total assets of $209.23T, but retained earnings are deeply negative and leverage is low (short-term debt $10.18T; no long-term debt). Shareholder returns are pressured: the stock is down ~-70.4% over 1 year with no dividend and no reported buybacks in the quarter. Analyst consensus targets a $1.50 share price, which is above the provided current price context ($0.6487), but momentum is strongly negative."

Revenue Growth

Neutral

Q1 2026 revenue was $75.55B, up ~+0.8% QoQ but down ~-21.4% YoY versus Q1 2025 ($96.03B). The trajectory over the last year shows contraction.

Profitability

Neutral

Gross margin improved versus Q4 2025 (31.6% vs 32.5% slightly down) but remains volatile (lower than Q1 2025 ~32.1%). Net margin is deeply negative at -19.5% in Q1 2026; net losses widened YoY (~-57%).

Cash Flow Quality

Neutral

Operating cash flow turned sharply negative in Q1 2026 (-$4.66B) versus near breakeven in Q4 2025 (-$0.01B) and positive in Q2 2025 ($33.6M). Free cash flow also remained negative (-$5.09B). No dividends/buybacks support cash returns.

Leverage & Balance Sheet

Fair

Low leverage with no long-term debt (short-term debt only: ~$10.18T) and very high cash/short-term investments (~$46.82T). However, retained earnings are severely negative and total equity has been unstable over the year.

Shareholder Returns

Neutral

1-year price change is -70.38% and there is no dividend yield provided. With no meaningful buyback data in the quarter, total shareholder returns are strongly negative.

Analyst Sentiment & Valuation

Caution

Consensus price target ($1.50) is above the provided current price ($0.6487), implying potential upside. However, severe recent price momentum is a risk to sentiment.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Q1 2026 delivered strong top-line momentum led by SteadyMD virtual care and multiple Mobile Health lines, prompting an upward 2026 revenue guide to $300M–$315M. SteadyMD accelerated to >$9M revenue with ~1.1M visits/lab orders (+38% YoY) and secured a new online-pharmacy contract for weight-loss plus broader clinical services. However, profitability remained pressured: adjusted EBITDA was -$10.2M and consolidated gross margin fell due to SteadyMD hiring inefficiencies (~-60 bps) and elevated fuel costs (each $1 increase ≈35 bps; March $3.69/gal vs $2.93 earlier; Q2 still ~ $4). Management kept adjusted EBITDA guidance (-$5M to -$10M) unchanged, indicating revenue gains are being offset by transport margin headwinds through 2Q and a lag in cost-cutting benefits into Q2 (full impact expected in Q3). Cash declined to $59.9M as migrant AR collections were delayed, adding near-term working-capital risk even as volumes improved across core segments.

AI IconGrowth Catalysts

  • SteadyMD virtual care accelerated: >$9M Q1 revenue, ~1.1M total visits & lab orders, +38% YoY; new weight-loss + general clinical services contract with a leading online pharmacy
  • Mobile phlebotomy operating momentum: projecting up to 75% 2026 growth; home visits rising from ~600/day to ~900/day by end of 2026; new territories Upstate NY and Pennsylvania; planned Florida launch
  • Care gap closure / PCP / longitudinal care expansion: surpassed 1.6M lives assigned since inception; visits +46% YoY; PCP panel >1,000 patients (majority enrolled in Q1); break-even target for PCP/longitudinal by late 2026

Business Development

  • SteadyMD: new contract with leading online pharmacy for virtual care services for weight loss prescriptions plus broad general clinical services
  • Medical transportation renewals/expansions: renewed 1 major NY hospital system for 1 year; renewed another major NY health system for 2 years and added Staten Island facilities
  • Medical transportation: contract for long-term acute care hospital in Chattanooga, TN
  • Medical transportation: hospice medical transportation contracts in Wisconsin
  • U.K. nonemergency patient transport: new contract with Great Western Hospitals NHS Foundation Trust
  • Working with a major national lab: integrated order intake into lab applications so doctors can order home visits directly through lab systems

AI IconFinancial Highlights

  • Revenue: $75.6M Q1 2026 vs $96.0M Q1 2025; YoY decline entirely from wind-down of migrant-related projects; excluding migrant revenue, revenue +24% YoY
  • SteadyMD added ~$9.5M revenue in Q1 2026 (acquired in Q4 2025)
  • Underlying revenue growth: removing migrant revenue and SteadyMD impact, revenue still +~8% YoY
  • Adjusted EBITDA: -$10.2M vs -$3.9M in Q1 2025
  • Adjusted gross margin: 31.6% in Q1 2026 vs 32.1% in Q1 2025
  • Underlying adjusted gross margin: 31.9% in Q1 2026 vs 30.4% in Q1 2025 (about +1.5 points) when comparing only business lines active in both periods (excludes migrant and SteadyMD deltas as described)
  • Consolidated gross margin hit: ~-60 bps from SteadyMD labor inefficiencies (incentives during clinician hiring gap)
  • Fuel headwind: estimated every $1 pump increase costs ~35 bps consolidated gross margin; March avg price paid $3.69 vs $2.93 in Jan/Feb; Q2-to-date still elevated (~running about $4)
  • Segment gross margins: Medical Transportation 31.9% vs 30.8% YoY (+110 bps); Mobile Health 31.0% vs 30.8% (+20 bps); SteadyMD several points lower than normal (expected to reverse starting Q2)
  • Operating expense trend: SG&A (excluding depreciation, stock-based comp, and other nonrecurring items) decreased from $35.7M in Q4 2025 to $34.1M in Q1 2026; management expects sequential SG&A declines in $ terms as year progresses
  • Cash: total cash/cash equivalents incl. restricted cash & investments $59.9M at Mar 31 2026 vs $68.3M end of 2025; lower due to delayed collection of NYC HPD migrant-related AR; ~$8M received Apr 1 2026 with remainder still being collected

AI IconCapital Funding

  • Cash runway: $59.9M total cash incl. restricted cash/investments at Mar 31 2026; management expects further near-term cash declines due to Q2 operating losses and working capital needs; expects easing in 2H 2026 with planned return to profitability
  • Buyback/debt: no buyback amounts or debt levels discussed in provided transcript

AI IconStrategy & Ops

  • SteadyMD: scaled clinical workforce by >45% using DocGo recruiting expertise; added workforce expected to meet pent-up demand in 2H 2026; margin drag from aggressive hiring expected to reverse starting Q2
  • Mobile Health tech integration: working with a major national lab to integrate order intake into lab applications enabling direct doctor orders through lab systems; deploying AI automation for order intake and customer service to increase margins
  • Cost-cutting lag: operating expense cuts made late Q4 into 2026 won’t materially impact income statement until Q2; full cost savings impact expected in Q3
  • Optimization focus: expects sequential SG&A dollar declines throughout 2026 supported by efficiency portfolio initiative and ongoing cuts

AI IconMarket Outlook

  • 2026 revenue guidance increased to $300M–$315M from $290M–$310M; midpoint referenced by management as ~$307.5M vs prior ~$295M midpoint (incremental ~$12M total)
  • 2026 adjusted EBITDA guidance unchanged at -$5M to -$10M
  • Fuel pricing assumption: current ~$4 running rate; management expects relief unlikely beyond 2Q (pressure through 2Q)
  • PCP/longitudinal care break-even: targeted for late 2026

AI IconRisks & Headwinds

  • Gross margin pressure from SteadyMD hiring gap: ~-60 bps consolidated gross margin
  • Fuel cost volatility tied to Middle East war: estimated ~35 bps consolidated gross margin impact per $1 increase; Q2-to-date still elevated around ~$4
  • Contract economics: most contracts lack automatic indexed cost adjustments; limited/no direct fuel indexing on leased-hour arrangements
  • Labor inefficiencies: higher-than-planned effective hourly wages for field labor restraining Medical Transportation gross margins
  • Working capital: delayed collection of migrant-related accounts receivable from NYC HPD reduced cash in Q1; near-term cash decline risk persists with additional operating losses and working capital requirements in Q2

Q&A: Analyst Interest

  • Topic: SteadyMD pipeline mix (new logos vs existing customer growth) and customer types; Management's detailed response: Growth is coming from both expanding existing customer capacity/volumes and adding new logos consistently since late last year. Customer demand spans online pharmacies (including weight loss), digital health/wellness/wearables, and typical labs. Integration with DocGo in-home visits is emphasized to expand telehealth capacity and margins throughout 2026.
  • Topic: Why reiterated EBITDA despite higher revenue (tailwinds vs headwinds); Management's detailed response: Management reiterated EBITDA because revenue upside is offset by transport gross margin pressure from fuel through Q2 (March ~$3.69 vs Jan/Feb ~$2.93; now running near ~$4). They estimate fuel impact of ~0.33–0.5 gross margin and note operating expense cuts are lagging, with conservatism due to temps running hot into Q2.
  • Topic: Care gap closure / payer priorities and incremental payer cadence; Management's detailed response: Payer needs remain consistent: care gap closure for “falling through the cracks” and unattached patients. Management added services around PCP attainment because many patients lack documented PCPs and opt to be made their PCPs. They cite patient complexity drivers (60% with 2+ chronic conditions; 42% previously undocumented). On logos, they said they remain on pace for 2–4 new payers in 1H 2026.

Sentiment: MIXED

Note: This summary was synthesized by AI from the DCGO Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for DCGO.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (DCGO)

© 2026 Stock Market Info — DocGo Inc. (DCGO) Financial Profile